Skip to main content


Pharming announces results from clinical trials for the treatment of COVID-19 with RUCONEST®

Clinical trials

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) announces the topline results from two randomized, open label, controlled, pilot clinical trials of patients hospitalized with COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the 7-point WHO ordinal scale on Day 7.

Read more


  • Cookies: This website uses cookies Check the cookies page for more information Accept Decline